Top

Obesity Surgery

Published in:

01-04-2014 | Other

Bariatric Surgery in Class I Obesity

A Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)

Authors: Luca Busetto, John Dixon, Maurizio De Luca, Scott Shikora, Walter Pories, Luigi Angrisani

Published in: Obesity Surgery | Issue 4/2014

Abstract

Class I obesity conveys an increased risk of comorbidities, impairs physical and mental health-related quality of life, and it is associated to an increased psychosocial burden, particularly in women. The need for effective and safe therapies for class I obesity is great and not yet met by nonsurgical approaches. Eligibility to bariatric surgery has been largely based on body mass index (BMI) cut points and limited to patients with more severe obesity levels. However, obese patients belonging to the same BMI class may have very different levels of health, risk, and impact of obesity on quality of life. Individual patients in class I obesity may have a comorbidity burden similar to, or greater than, patients with more severe obesity. Therefore, the denial of bariatric surgery to a patient with class I obesity suffering from a significant obesity-related health burden and not achieving weight control with nonsurgical therapy simply on the basis of the BMI level does not appear to be clinically justified. A clinical decision should be based on a more comprehensive evaluation of the patient’s current global health and on a more reliable prediction of future morbidity and mortality. After a careful review of available data about safety and efficacy of bariatric surgery in patients with class I obesity, this panel reached a consensus on ten clinical recommendations.

Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metrics. 2012;10:22.

Sturm R. Increases in morbid obesity in the USA: 2000–2005. Public Health. 2007;121:492–6.PubMedCentralPubMed

Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol. 2013;9:13–27.PubMed

Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71–82.PubMed

Finkelstein EA, Brown DS, Wrage LA, et al. Individual and aggregate years-of-life-lost associated with overweight and obesity. Obesity. 2010;18:333–9.PubMed

Zheng W, McLerran DF, Rolland B, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011;364:719–29.PubMed

WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.

Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308:581–90.PubMedCentralPubMed

Jerant A, Franks P. Body mass index, diabetes, hypertension, and short-term mortality: a population-based observational study, 2000–2006. J Am Board Fam Med. 2012;25:422–31.PubMed

10.

Doehner W, Erdmann E, Cairns R, et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol. 2012;162:20–6.PubMed

11.

Kokkinos P, Myers J, Faselis C, et al. BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. Diabetes Care. 2012;35:1021–7.PubMedCentralPubMed

12.

Tseng CH. Obesity paradox: differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. Atherosclerosis. 2013;226:186–92.PubMed

13.

The Look AHEAD Research Group. Cardiovascular effects of intesive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.

14.

Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg. 2011;253:484–7.PubMed

15.

Amundson DE, Djurkovic S, Matwiyoff GN. The obesity paradox. Crit Care Clin. 2010;26:583–96.PubMed

16.

Morse SA, Gulati R, Reisin E. The obesity paradox and cardiovascular disease. Curr Hypertens Rep. 2010;12:120–6.PubMed

17.

Oreopoulos A, Kalantar-Zadeh K, Sharma AM, et al. The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med. 2009;25:643–59.PubMed

18.

Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481–6.PubMed

19.

Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961–9.PubMed

20.

Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–34.PubMed

21.

Lindström D, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish diabetes prevention study. Lancet. 2006;368:1673–9.PubMed

22.

Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374:1677–86.PubMedCentral

23.

Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008;207:928–34.PubMed

24.

Livingston EH, Chandalia M, Abate N. Do current body mass index criteria for obesity surgery reflect cardiovascular risk? Surg Obes Relat Dis. 2007;3:577–85.PubMed

25.

Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol. 2010;316:104–8.PubMed

26.

Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.PubMed

27.

Keating CL, Peeters A, Swinburn BA, et al. Utility-based quality of life associated with overweight and obesity: the Australian diabetes, obesity, and lifestyle study. Obesity. 2013;21:652–5.PubMed

28.

Kolotkin RL, Crosby RD, Pendleton R, et al. Health-related quality of life in patients seeking gastric bypass surgery vs non-treatment-seeking controls. Obes Surg. 2003;13:371–7.PubMed

29.

Everson SA, Maty SC, Lynch JW, et al. Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. J Psychosom Res. 2002;53:891–5.PubMed

30.

Colles SL, Dixon JB, O’Brien PE. Binge eating disorder: prevalence and correlates in sub-groups of the Australian population. Asia Pac J Clin Nutr. 2005;14:S109.

31.

McCrea RL, Berger YG, King MB. Body mass index and common mental disorders: exploring the shape of the association and its moderation by age, gender and education. Int J Obes. 2012;36:414–21.

32.

Seidell JC. Societal and personal costs of obesity. Exp Clin Endocrinol Diabetes. 1998;106:7–9.PubMed

33.

Finkelstein EA, Di Bonaventura M, Burgess SM, et al. The costs of obesity in the workplace. J Occup Environ Med. 2010;52:971–6.PubMed

34.

National Institutes of Health National Institutes of Health. National Heart, Lung and Blood Institute: clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. The Evidence Report, June 1998.

35.

National Institute for Health and Clinical Excellence. Obesity. Guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE Clin Guidelines. 2006;43:1–84.

36.

Avenell A, Brown TJ, McGee MA, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17:317–35.PubMed

37.

Tuomilehto J, Lindström D, Eriksson GE, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.PubMed

38.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMedCentral

39.

Rawal LB, Tapp RJ, Williams ED, et al. Prevention of type 2 diabetes and its complications in developing countries: a review. Int J Behav Med. 2012;19:121–33.PubMedCentralPubMed

40.

The Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. One-year results of the Look AHEAD trial. Diabetes Care. 2007;30:1374–83.

41.

The Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individual with type 2 diabetes mellitus. Four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566–75.PubMedCentral

42.

Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308:2489–96.PubMed

43.

Heymsfield SB, van Mierlo CA, van der Knaap HC, et al. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord. 2003;27:537–49.PubMed

44.

Chearskul S, Delbridge E, Shulkes A, et al. Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations. Am J Clin Nutr. 2008;87:1238–46.PubMed

45.

Mulholland Y, Nicokavoura E, Broom J, et al. Very-low-energy diets and morbidity: a systematic review of longer-term evidence. Br J Nutr. 2012;108:832–51.PubMed

46.

Baker S, Jerums PJ. Effects and clinical potential of very-low-calorie diets (VLCDs) in type 2 diabetes. Diabetes Res Clin Pract. 2009;85:235–42.PubMed

47.

Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579–84.PubMed

48.

Anderson JW, Vichitbandra S, Qian W, et al. Long-term weight maintenance after an intensive weight-loss program. J Am Coll Nutr. 1999;18:620–7.PubMed

49.

Lantz H, Peltonen M, Agren L, et al. Intermittent versus on-demand use of a very low calorie diet: a randomized 2-year clinical trial. J Intern Med. 2003;253:463–71.PubMed

50.

Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr. 2006;84:304–11.PubMed

51.

Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71–7.PubMed

52.

Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167–73.PubMed

53.

Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.PubMed

54.

Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.PubMed

55.

Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo controlled, phase 3 trial. Lancet. 2011;377:1341–52.PubMed

56.

Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.PubMedCentralPubMed

57.

Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.PubMed

58.

Apovian C, Aronne L, Rubino D, et al. A randomized, phase 3 trial of Naltrexone SR/Bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935–43.

59.

Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.PubMedCentralPubMed

60.

Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.PubMed

61.

Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–16.PubMed

62.

Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843–54.

63.

Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15:1161–4.PubMed

64.

Verdam FJ, Schouten R, Greve JW, et al. An update on less invasive and endoscopic techniques mimicking the effect of bariatric surgery. J Obes. 2012;2012:597871.PubMedCentralPubMed

65.

Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the endobarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251:236–43.PubMed

66.

Sandler BJ, Rumbaut R, Swain CP, et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc. 2011;25:3028–33.PubMed

67.

Gastrointestinal surgery for severe obesity. National Institutes of Health consensus development conference draft statement. Obes Surg 1991;1:257–66.

68.

Fried M, Hainer V, Basdevant A, et al. Inter-disciplinary European guidelines on surgery of severe obesity. Int J Obes. 2007;31:569–77.

69.

Rubino F, Kaplan LM, Schauer PR, et al. The diabetes surgery summit consensus conference recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251:399–405.PubMed

70.

American Diabetes Association. Summary of revisions for the 2009 clinical practice recommendations. Diabetes Care. 2009;32:S3–5.

71.

Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med. 2011;28:628–42.PubMedCentralPubMed

72.

Australian Government - National Health and Medical Research Council - Department of Health and Ageing. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia, 2013.

73.

Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2013;9:159–91.PubMed

74.

ASMBS Clinical Issues Committee. Bariatric surgery in class I obesity (BMI 30–35 kg/m²). Surg Obes Relat Dis. 2013;9:e1–e10.

75.

Müller MJ, Lagerpusch M, Enderle J, et al. Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome. Obes Rev. 2012;13:6–13.PubMed

76.

Okorodudu DO, Jumean MF, Montori VM, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes. 2010;34:791–9.

77.

Thomas EL, Frost G, Taylor-Robinson SD, et al. Excess body fat in obese and normal-weight subjects. Nutr Res Rev. 2012;25:150–61.PubMed

78.

Kragelund C, Omland T. A farewell to body-mass index? Lancet. 2005;366:1589–91.PubMed

79.

Deurenberg P, Deurenberg-Yap M. Validity of body composition methods across ethnic population groups. Forum Nutr. 2003;56:299–301.PubMed

80.

Habbu A, Lakkis NM, Dokainish H. The obesity paradox: fact or fiction? Am J Cardiol. 2005;98:944–8.

81.

Fonarow GC, Srikanthan P, Costanzo MR, et al. An obesity paradox in acute heart failure: analysis of body mass index and in hospital mortality for 109,927 patients in the acute decompensated heart failure national registry. Am Heart J. 2007;153:74–81.PubMed

82.

Oreopoulos A, Padwal R, Kalantar-zadeh K, et al. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156:13–22.PubMed

83.

Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis. 2005;46:489–500.PubMed

84.

Galal W, van Gestel YR, Hoeks SE, et al. The obesity paradox in patients with peripheral arterial disease. Chest. 2008;134:925–30.PubMed

85.

Hastie CE, Padmanabhan S, Slack R, et al. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31:222–6.PubMed

86.

Diercks D, Roe MT, Mulgund J, et al. The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the American College of Cardiology/American Heart Association guidelines quality improvement initiative. Am Heart J. 2006;152:140–8.PubMed

87.

Mullen JT, Moorman DW, Davenport DL. The obesity paradox. Ann Surg. 2009;250:166–72.PubMed

88.

Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003;144:5159–65.PubMed

89.

Montani JP, Carroll JF, Dwyer TM, et al. Ectopic fat storage in the heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord. 2004;28:S58–65.PubMed

90.

Matsuzawa Y, Nakamura T, Shimomura I, et al. Visceral fat accumulation and cardiovascular disease. Obes Res. 1995;3:S645–7.

91.

Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–7.PubMed

92.

Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609–16.PubMed

93.

Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factors clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168:1617–24.PubMed

94.

International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. IDF Publications 2005.

95.

Heitmann BL, Lissner L. Hip hip hurrah! Hip size inversely related to heart disease and total mortality. Obes Rev. 2011;12:478–81.PubMed

96.

Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061–7.PubMed

97.

Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106:15430–5.PubMedCentralPubMed

98.

Iacobellis G, Malavazos AE, Corsi MM. Epicardial fat: from the biomolecular aspects to the clinical practice. Int J Biochem Cell Biol. 2011;43:1651–4.PubMed

99.

Pories WJ, Dohm LG, Mansfield CJ. Beyond the BMI: the search for better guidelines for bariatric surgery. Obesity. 2010;18:865–71.PubMed

100.

Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes. 2009;33:289–95.

101.

Padwal RS, Pajewski NM, Allison DB, et al. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ. 2011;183:E1059–66.PubMedCentralPubMed

102.

Kuk JL, Ardern CI, Church TS, et al. Edmonton obesity staging system: association with weight history and mortality risk. Appl Physiol Nutr Metab. 2011;36:570–6.PubMed

103.

Gill RS, Karmali S, Sharma AM. The potential role of the Edmonton obesity staging system in determining indications for bariatric surgery. Obes Surg. 2011;21:1947–9.PubMed

104.

Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007;142:621–35.PubMed

105.

Thomas H, Agrawal S. Systematic review of obesity surgery mortality risk score—preoperative risk stratification in bariatric surgery. Obes Surg. 2012;22:1135–40.PubMed

106.

The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445–54.

107.

De Maria EJ, Portenier D, Wolfe L. Obesity surgery mortality risk score: proposal for a clinically useful score to predict mortality risk in patients undergoing gastric bypass. Surg Obes Relat Dis. 2007;3:134–40.

108.

Blackstone RP, Cortes MC. Metabolic acuity score: effect on major complications after bariatric surgery. Surg Obes Relat Dis. 2010;6:267–73.PubMed

109.

Turner PL, Saager L, Dalton J, et al. A nomogram for predicting surgical complications in bariatric surgery patients. Obes Surg. 2011;21:655–62.PubMed

110.

O’Brien PE, Dixon JB, Laurie C, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med. 2006;144:625–33.PubMed

111.

Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23.PubMed

112.

Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146:143–8.PubMed

113.

Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;26(366):1567–76.

114.

Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y Gastric Bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. The diabetes surgery study randomized clinical trial. JAMA. 2013;309:2240–9.PubMed

115.

Li Q, Chen L, Yang Z, et al. Metabolic effects of bariatric surgery in type 2 diabetic patients with body mass index of 35 kg/m². Diabetes Obes Metab. 2012;14:262–70.PubMed

116.

Shah SS, Todkar JS, Shah PS, et al. Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index of 35 kg/m². Surg Obes Relat Dis. 2010;6:332–8.PubMedCentralPubMed

117.

Huang CK, Shabbir A, Lo CH, et al. Laparoscopic Roux-en-Y gastric bypass for the treatment of type II diabetes mellitus in Chinese patients with body mass index of 25–35. Obes Surg. 2011;21:1344–9.PubMedCentralPubMed

118.

De Sa VC, Ferraz AA, Campos JM, et al. Gastric bypass in the treatment of type 2 diabetes in patients with a BMI of 30 to 35 kg/m². Obes Surg. 2011;21:283–7.PubMed

119.

Cohen R, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420–8.PubMedCentralPubMed

120.

Ferzli GS, Dominique E, Ciaglia M, et al. Clinical improvement after duodenojejunal bypass for nonobese type 2 diabetes despite minimal improvement in glycemic homeostasis. World J Surg. 2009;33:972–9.PubMed

121.

Geloneze B, Geloneze SR, Fiori C. Surgery for nonobese type 2 diabetic patients: an interventional study with duodeno-jejunal exclusion. Obes Surg. 2009;19:1077–83.PubMed

122.

Ramos AC, Galvao MP, de Souza YM. Laparoscopic duodenal–jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 kg/m² (LBMI). Obes Surg. 2009;19:307–12.PubMed

123.

Scopinaro N, Papadia F, Marinari G, et al. Long-term control of type 2 diabetes mellitus and other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI < 35 kg/m². Obes Surg. 2007;17:185–92.PubMed

124.

Chiellini C, Rubino F, Castagneto M, et al. The effects of bilio-pancreatic diversion on type 2 diabetes in patients with BMI < 35 kg/m². Diabetologia. 2009;52:1027–30.PubMed

125.

Scopinaro N, Adami GF, Papadia FS, et al. The effects of biliopancreatic diversion on type 2 diabetes mellitus in patients with mild obesity (BMI 30–35 kg/m²) and simple overweight (BMI 25–30 kg/m²): a prospective controlled study. Obes Surg. 2011;21:880–8.PubMed

126.

Lee WJ, Wang W, Lee YC, et al. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI > 35 kg/m². J Gastrointest Surg. 2008;12:945–52.PubMed

127.

Lee WJ, Chong K, Chen CY, et al. Diabetes remission and insulin secretion after gastric bypass in patients with body mass index < 35 kg/m². Obes Surg. 2011;21:889–95.PubMed

128.

De Paula AL, Macedo ALV, Schraibman V, et al. Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20–34. Surg Endosc. 2009;23:1724–32.

129.

Reis CEG, Alvarez-Leite JI, Bressan J, et al. Role of bariatric–metabolic surgery in the treatment of obese type 2 diabetes with body mass index < 35 kg/m²: a literature review. Diab Technol Ther. 2012;14(4):365–72.

130.

Cohen R, Caravatto PP, Correa JL, et al. Glycemic control after stomach-sparing duodenal–jejunal bypass surgery in diabetic patients with low body mass index. Surg Obes Relat Dis. 2012;8:375–80.PubMed

131.

Maglione MA, Gibbons MM, Livhits M, et al. Bariatric surgery and nonsurgical therapy in adults with metabolic conditions and a body mass index of 30.0 to 34.9 kg/m². Rockville: Agency for Healthcare Research and Quality (US); 2013.

132.

Parikh M, Issa R, Vieira D, et al. Role of bariatric surgery as treatment for type 2 diabetes in patients who do not meet current NIH criteria: a systematic review and meta-analysis. J Am Coll Surg. 2013;217:527–32.PubMed

133.

Flum DR, Belle SH, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445–54.PubMed

134.

De Maria EJ, Winegar DA, Pate VW, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the bariatric outcomes longitudinal database. Ann Surg. 2010;252:559–66.

135.

Parikh M, Duncombe J, Fielding GA. Laparoscopic adjustable gastric banding for patients with body mass index < 35 kg/m². Surg Obes Relat Dis. 2006;2:518–22.PubMed

136.

Sultan S, Parikh M, Youn H, et al. Early U.S. outcomes after laparoscopic adjustable gastric banding in patients with a body mass index less than 35 kg/m². Surg Endosc. 2009;23:1569–73.PubMed

137.

Choi J, Digiorgi M, Milone L, et al. Outcomes of laparoscopic adjustable gastric banding in patients with low body mass index. Surg Obes Relat Dis. 2010;6:367–71.PubMed

138.

Kakoulidis TP, Karringer A, Gloaguen T, et al. Initial results with sleeve gastrectomy for patients with class I obesity (BMI 30–35 kg/m²). Surg Obes Relat Dis. 2009;5:425–8.PubMed

139.

Abbatini F, Capoccia D, Casella G, et al. Type 2 diabetes in obese patients with body mass index of 30–35 kg/m²: sleeve gastrectomy versus medical treatment. Surg Obes Relat Dis. 2012;8:20–4.PubMed

140.

Angrisani L, Favretti F, Furbetta F, et al. Italian group for lap-band system: results of multicenter study on patients with BMI r 35 kg/m². Obes Surg. 2004;14:415–8.PubMed

141.

Serrot FJ, Dorman RB, Miller CJ, et al. Comparative effectiveness of bariatric surgery and nonsurgical therapy in adults with type 2 diabetes mellitus and body mass index of 35 kg/m². Surgery. 2011;150:684–91.PubMed

142.

Frenken M, Cho EY. Metabolic intestinal bypass surgery for type 2 diabetes in patients with a BMI of 35 kg/m²: comparative analysis of 16 patients undergoing either BPD, BPD-DS, or RYGB. Obes Facts. 2011;4:13–7.PubMed

143.

Gianos M, Abdemur A, Fendrich I, et al. Outcomes of bariatric surgery in patients with body mass index < 35 kg/m². Surg Obes Relat Dis. 2012;8:25–30.PubMed

144.

Angrisani L, Cutolo PP, Formisano GP, et al. Long-term outcomes of laparoscopic adjustable silicone gastric banding (LAGB) in moderately obese patients with and without co-morbidities. Obes Surg. 2013;23:897–902.PubMed

145.

Deitel M. Slow-progression, autoimmune, type 1 diabetes in adults: a cause of failure of resolution of diabetes after bariatric surgery. Surg Obes Relat Dis. 2009;5:705–6.PubMed

146.

Deitel M. Update: why diabetes does not resolve in some patients after bariatric surgery. Obes Surg. 2011;21:794–6.PubMed

147.

Wells JC. Ethnic variability in adiposity, thrifty phenotypes and cardiometabolic risk: addressing the full range of ethnicity, including those of mixed ethnicity. Obes Rev. 2012;13 Suppl 2:14–29.PubMed

148.

WHO. Obesity: preventing and managing the global epidemic. Report of a who consultation. World Health Organ Tech Rep Ser. 2000;894:1–253.

149.

Inge TH, Krebs NF, Garcia VF, et al. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics. 2004;114:217–23.PubMed

150.

Baur LA, Fitzgerald DA. Recommendations for bariatric surgery in adolescents in Australia and New Zealand. J Paediatr Child Health. 2010;46:704–7.PubMed

151.

Bannerman E, Miller MD, Daniels LA, et al. Anthropometric indices predict physical function and mobility in older Australians: the Australian longitudinal study of ageing. Public Health Nutr. 2002;5:655–62.PubMed

152.

Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364:1218–29.PubMedCentralPubMed

153.

Houston DK, Nicklas BJ, Zizza CA. Weighty concerns: the growing prevalence of obesity among older adults. J Am Diet Assoc. 2009;109:1886–95.PubMed

154.

Zajacova A, Ailshire J. Body mass trajectories and mortality among older adults: a joint growth mixture-discrete-time survival analysis. Gerontologist 2013 Jan 25 [Epub ahead of print].

155.

Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23:427–36.PubMed

156.

Picot J, Jones J, Colquitt JL, et al. Weight loss surgery for mild to moderate obesity: a systematic review and economic evaluation. Obes Surg. 2012;22:1496–506.PubMed

157.

Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211–9.PubMed

158.

Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery. A systemic review and meta-analysis. JAMA. 2004;292:1724–37.PubMed

159.

Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000;232:515–29.PubMedCentralPubMed

160.

DePaula AL, Stival A, Halpern A, et al. Thirty-day morbidity and mortality of the laparoscopic ileal interposition associated with sleeve gastrectomy for the treatment of type 2 diabetic patients with BMI < 35: an analysis of 454 consecutive patients. World J Surg. 2011;35:102–8.PubMed

161.

McKneally MF, Daar AS. Introducing new technologies: protecting subjects of surgical innovation and research. World J Surg. 2003;27:930–5.PubMed

162.

Roman S, Napoleon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14:539–44.PubMed

163.

Champion JK, Williams M, Champion S, et al. Implantable gastric stimulation to achieve weight loss in patients with a low body mass index: early clinical results. Surg Endosc. 2006;20:444–7.PubMed

164.

Afterburner DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23:93–102.

165.

Ritz P, Hanaire H. Post-bypass hypoglycaemia: a review of the current findings. Diabetes Metab. 2011;37:274–81.PubMed

166.

Lerner H, Whang J, Nipper R. Benefit–risk paradigm for clinical trial design of obesity devices: FDA proposal. Surg Endosc. 2013;27:702–7.PubMed

167.

Reinhold RB. Critical analysis of long term weight loss following gastric bypass. Surg Gynecol Obstet. 1982;155:385–94.PubMed

168.

Metropolitan height and weight tables. 64, 3–9. 1983. New York, Metropolitan Life Foundation. Statistical Bulletin

169.

Committee on Standards for Reporting Results, American Society for Bariatric Surgery. Standards for reporting results. Obes Surg 1994;4:56–65.

170.

Junior WS, Campos CS, Nonino CB. Reporting results after bariatric surgery: reproducibility of predicted body mass index. Obes Surg. 2012;22:519–22.PubMed

171.

Deitel M, Gawdat K, Melissas J. Reporting weight loss. Obes Surg. 2007;17:565–8.PubMed

172.

Belle SH, Berk PD, Courcoulas AP, et al. Reporting weight change: Standardized reporting accounting for baseline weight. Surg Obes Relat Dis. 2013;9:782–9.

173.

Sabin J, Fanelli R, Flaherty H, et al. Best practice guidelines on informed consent for weight loss surgery patients. Obes Res. 2005;13:250–3.PubMed

174.

Sarr MG, Billington CJ, Brancatisano R, et al. The EMPOWER study: randomized, prospective, double-blind, multicenter trail of vagal blockade to induce weight loss in morbid obesity. Obes Surg. 2012;11:1771–82.

175.

Shikora SA, Bergenstal R, Bessler M, et al. Implantable gastric stimulation for the treatment of clinically severe obesity: results of the SHAPE trial. Surg Obes Relat Dis. 2009;5:31–7.PubMed

Title: Bariatric Surgery in Class I Obesity
A Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
Authors: Luca Busetto
John Dixon
Maurizio De Luca
Scott Shikora
Walter Pories
Luigi Angrisani
Publication date: 01-04-2014
Publisher: Springer US
Published in: Obesity Surgery / Issue 4/2014
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-014-1214-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bariatric Surgery in Class I Obesity

A Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Postoperative Analgesia in Morbid Obesity

Laparoscopic Placement of Adjustable Gastric Band in Patients with Autoimmune Disease or Chronic Steroid Use

Does Patient Compliance with Follow-up Influence Weight Loss After Gastric Bypass Surgery? A Systematic Review and Meta-Analysis

Reply to “Still Controversies After Mini Gastric Bypass”

Predictors of Weight Loss are Different in Men and Women After Sleeve Gastrectomy

The Value of Continuous Wound Infusion Systems for Postoperative Pain Control Following Laparoscopic Roux-en-Y Gastric Bypass: an Analysis of Outcomes and Cost